Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study

Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study

The multicentric retrospective BIO-Ra study combined inflammatory indices from peripheral blood and clinical factors in a composite prognostic score for metastatic castration-resistant prostate cancer patients receiving Radium-223 (Ra-223). In the present study, we evaluated (i) the prognostic power...

Full description

Bibliographic Details
Main Authors: Matteo Bauckneht, Sara Elena Rebuzzi, Marta Ponzano, Roberto Borea, Alessio Signori, Viviana Frantellizzi, Elisa Lodi Rizzini, Manlio Mascia, Valentina Lavelli, Alberto Miceli, Maria Silvia De Feo, Antonio Rosario Pisani, Susanna Nuvoli, Vincenzo Tripoli, Alessio Giuseppe Morganti, Paolo Mammucci, Salvatore Caponnetto, Guglielmo Mantica, Angelo Domenico Di Nicola, Carlo Villano, Luca Cindolo, Silvia Morbelli, Gianmario Sambuceti, Stefano Fanti, Renato Patrizio Costa, Angela Spanu, Giuseppe Rubini, Fabio Monari, Giuseppe De Vincentis, Giuseppe Fornarini
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
metastatic castration-resistant prostate cancer
Radium-223
inflammatory indices
neutrophil-to-lymphocyte ratio
clinical factors
treatment completion
Online Access:https://www.mdpi.com/2072-6694/14/7/1744

Internet

https://www.mdpi.com/2072-6694/14/7/1744

Similar Items